Lung cancer rising among non-smokers — here's why
The most common form of lung cancer is primarily found in non-smokers, a new study reveals. Doctors react to the surprising ...
Scientists identify feature of aggressive non-small cell lung cancer
In localized non-small cell lung cancer (NSCLC), a tumor's ability to use carbon from glucose to feed the tricarboxylic acid ...
HER2+ Non-Small Cell Lung Cancer Market is Predicted to Grow at a CAGR of 13.2% During the Study Period (2020–2034) | DelveInsight
The treatment landscape for HER2-positive NSCLC is rapidly evolving as research continues to reveal the genetic drivers of these tumors. Emerging therapies like Pyrotinib (Jiangsu HengRui Medicine), ...
Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Laboratory Illustrative image Ridgefield, Conn., U.S., and Ingelheim, Germany Zongertinib would be the first orally ...
Cure Today3d
Learning to Live with Advanced Non-Small Cell Lung Cancer
Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: ...
Extensive-Stage Small Cell Lung Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
The leading Extensive-Stage Small Cell Lung Cancer Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, ...
PharmiWeb2d
Boehringer’s zongertinib receives Priority Review…
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...
Antibody therapy shrinks immunotherapy-resistant lung cancer tumors in mice
An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...
Science Daily5d
Lung cancer cells can go 'off grid'
Researchers have found that some particularly aggressive lung cancer cells can develop their own electric network, like that seen in the body's nervous system.
Morningstar3d
Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
“We believe zongertinib has the potential to transform the care of previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer and are hopeful about the continued ...